University of Oxford Confidence in Concept Scheme – Round 5
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- University of Oxford (Lead Research Organisation)
- University of Plymouth (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- UCB Pharma (Collaboration)
- University of Dundee (Collaboration)
- DIAMOND LIGHT SOURCE (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Mahidol University (Collaboration)
- Bioinduction (Collaboration)
- London School of Hygiene and Tropical Medicine (LSHTM) (Collaboration)
- Stanford University (Collaboration)
- PharmGenomics GmbH (Collaboration)
- Walter Reed Army Institute of Research (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
People |
ORCID iD |
Publications
Fletcher NF
(2017)
TNF superfamily members promote hepatitis C virus entry via an NF-?B and myosin light chain kinase dependent pathway.
in The Journal of general virology
Gonçalves-Carneiro D
(2017)
The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis.
in Journal of virology
Grove J
(2017)
A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.
in Wellcome open research
Hedegaard DL
(2017)
High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.
in Journal of hepatology
Horton C
(2020)
Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy.
in Stem cells (Dayton, Ohio)
Hou MM
(2022)
Impact of a blood-stage vaccine on Plasmodium vivax malaria.
in medRxiv : the preprint server for health sciences
Ko C
(2018)
Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
in Journal of hepatology
Lai AG
(2018)
Glucose and glutamine availability regulate HepG2 transcriptional responses to low oxygen.
in Wellcome open research
Lee AW
(2019)
A knottin scaffold directs the CXC-chemokine-binding specificity of tick evasins.
in The Journal of biological chemistry
Lemoine C
(2020)
Technological Approaches for Improving Vaccination Compliance and Coverage.
in Vaccines
| Description | Participation in P. vivax CHMI workshop |
| Geographic Reach | Asia |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | A novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections: preclinical proof of concept |
| Amount | £55,000 (GBP) |
| Organisation | BactiVac Network |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2019 |
| Description | An automated macrocycle discovery platform targeting intracellular protein-protein interactions |
| Amount | £350,000 (GBP) |
| Funding ID | 105391 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 02/2022 |
| Description | Biotherapeutics Expert Review Panel |
| Amount | £300,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2021 |
| Description | Chair Award - Shoumo Bhattacharya Project |
| Amount | £409,625 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Confidence in Concept Award |
| Amount | £72,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 11/2018 |
| Description | Departmental PhD studentship for Rik van der Veen, Nuffield Dept. of Medicine, University of Oxford |
| Amount | £95,430 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Departmental PhD studentship for Romain Guyon, Nuffield Dept. of Medicine, University of Oxford |
| Amount | £95,430 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2022 |
| Description | Developing small molecule inhibitors for a rare childhood seizure disorder - YUE Project |
| Amount | £246,406 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | EPA Trust Research Grant |
| Amount | £67,777 (GBP) |
| Funding ID | RF 254 |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 09/2019 |
| Description | Experimental Medicine |
| Amount | £2,072,653 (GBP) |
| Funding ID | MR/X005321/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| End | 11/2027 |
| Description | Exploiting the Epigenetic Memory of iPS Cells for the Production of Dendritic Cells Predisposed to the Induction of Tolerance: Guy Newton Translational Fund - Paul Fairchild Project |
| Amount | £24,904 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Horizon-HLTH-2022: Optimising a High Efficacy Plasmodium vivax Malaria Vaccine (OptiViVax) |
| Amount | £11,000,000 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 12/2022 |
| Description | Improving malaria vaccination with BCG: Global Challenges Research Fund (GCRF) - Anita Milicic Project |
| Amount | £50,000 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Jenner Institute Investigator |
| Amount | £3,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2019 |
| Description | Jenner Institute Investigator |
| Amount | £3,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2018 |
| Description | Jenner Investigator award |
| Amount | £2,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2020 |
| Description | MultiViVax |
| Amount | € 5,200,000 (EUR) |
| Funding ID | 733073 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2017 |
| End | 12/2021 |
| Description | Oxford Immune Intelligence |
| Amount | £90,409 (GBP) |
| Funding ID | USCF 443 |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| Description | P. vivax CHMI in Thailand |
| Amount | £846,222 (GBP) |
| Organisation | Mahidol Oxford Tropical Medicine Research Unit |
| Sector | Public |
| Country | Thailand |
| Start | |
| Description | Plasmodium vivax Volunteer Infection Studies in Thailand |
| Amount | £2,519,659 (GBP) |
| Funding ID | 212336/Z/18/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 09/2023 |
| Description | Polymeric-DNA nanoparticles: modular delivery systems for nucleic acid-based therapies - MLSTF, Andrew Turberfield Project |
| Amount | £72,890 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Preclinically test anti-Grem1 antibody - Simon Leedham Project |
| Amount | £98,000 (GBP) |
| Organisation | UCB Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Program Grant: Precision therapeutics for cardiovascular inflammation - Shoumo Bhattacharya project |
| Amount | £1,004,873 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Reprogramming human T cells for disease tolerance in falciparum malaria |
| Amount | £2,200,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2022 |
| Description | UCSF |
| Amount | £36,000 (GBP) |
| Organisation | University of Oxford |
| Department | Oxford University Innovation |
| Sector | Private |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 02/2019 |
| Description | Univeristy of Oxford - Confidence in Concept 2019 |
| Amount | £37,500 (GBP) |
| Funding ID | MC_PC_19049 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2022 |
| Title | Bug to Drug Yeast Surface Display Technology |
| Description | We developed a method to display tick proteins on the surface of yeast. This enabled us to clone high affinity chemokine ligands called evasins. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Reduction in animal use: previously ticks needed to be maintained on host animals to extract saliva. Our method clones the tick genes into yeast |
| Title | In vitro assay for assessment of antibodies against Plasmodium vivax |
| Description | We have established at the Jenner Institute an assay to assess the efficacy of antibodies generated by vaccination against Plasmodium vivax malaria. This assay uses a transgenic P. knowlesi malaria parasite adapted to human RBCs, cultured in the presence of polyclonal serum or monoclonal antibodies raised by vaccination with target antigens from P. vivax. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | We are developing new monoclonal antibodies therapeutics for P. vivax malaria and will use this assay to evaluate them. |
| Title | In vitro assays for antimicrobial resistance activity inhibition |
| Description | We have adapted published methods to measure antimicrobial resistance activity in vitro so that we can show their inhibition with new therapeutics. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | We are developing a new product for antimicrobial resistance and will use this assay to evaluate it |
| Title | PvDBP human mAbs |
| Description | Human antibodies to PvDBP_RII protein |
| Type Of Material | Antibody |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Grants submitted and publication in preparation |
| Description | Angela Russell |
| Organisation | University of Oxford |
| Department | Department of Pharmacology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Structure-based small molecule approach targeting Smoothened, the Hh signal transducer. |
| Collaborator Contribution | The group of Angela Russell will provide small molecules targeting Smoothened, which we will test functionally and, if an effect is observed, will also perform co-crystallisation with Smoothened. |
| Impact | The collaboration just started. |
| Start Year | 2015 |
| Description | Collaboration with the Drug Discovery Unit, University of Dundee - Alex Bullock Project |
| Organisation | University of Dundee |
| Department | Drug Discovery Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Drug development & provision of IP |
| Collaborator Contribution | Drug development |
| Impact | None yet |
| Start Year | 2018 |
| Description | Commercial DBS systems provided in-kind by Bioinduction UK Ltd to Professor Alex Green |
| Organisation | Bioinduction |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Testing the optimised parameters/frequencies through the DBS devices provided by Bioinduction Ltd. |
| Collaborator Contribution | Providing 5 commercial DBS devices and other know-how support |
| Impact | Still ongoing |
| Start Year | 2021 |
| Description | Dr. Manzano-Prof. Turberfield |
| Organisation | University of Oxford |
| Department | Department of Physics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The Confidence in Concept Scheme - Round 5, MC_PC_16056 project funding allowed me (Dr. Manzano) to build a collaboration with Prof. Turberfield´s team in Physics department (University of Oxford), and particularly with Dr. Antonio García Guerra to design a DNA-based nanoparticle to improve the delivery of oligonucleotides to the CNS. Particularly our team (Dr. Manzano-Prof. Wood) demonstrated the efficacy of delivering LNA-gapmer oligonuclotides to cells obtained from Amyotrophic Lateral Sclerosis patients (ALS)(work published in Brain journal 2017). Limitations in the efficacy of the delivery of these oligoes to motor neurons in vitro prevented this approach to be translated to in vivo models. Our team is currenly validating the ability of DNA-based nanoparticles to increase the delivery of the above mentioned oligoes to motor neurons in ALS patient cells and neuronal cell lines. Moreover, Dr. Manzano has suggested to include a motor neuron specific peptide she has been working on in the past, in these DNA-based nanoparticles to facilitate the uptake by these cells. The future aim will be validating this strategy in vivo in ALS animal models. |
| Collaborator Contribution | Prof. Turberfield´s team has modified DNA-based particles to carry the above mentioned oligoes to neuronal models in vitro. This team has also conjugated the motor neuron specific peptide suggested and provided by Dr. Manzano with the aim of improving the delivery of the oligoes published by Dr. Manzano (Brain 2017) to motor neurons. |
| Impact | The first output of this collaboration is the obtained funding from the CiC program. This is a multi-disciplinary collaboration involving Physics (particle synthesis) and Biological Sciences (use of the synthetic particles to solve a biological need y neuroscience discipline). |
| Start Year | 2017 |
| Description | Grem1 antibody |
| Organisation | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We are undertaking preclinical work up of a novel antibody developed by UCB Pharma |
| Collaborator Contribution | Provision of antibody and other reagents, expertise and lab services |
| Impact | pending |
| Start Year | 2016 |
| Description | Imperial College, London |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Compensation for collaborator's below contributions. Administering and supervising the mosquito challenge. |
| Collaborator Contribution | Accepting mosquitoes from Thailand, checking mosquito infectivity before and after challenge (own microscopists), and providing the facility for performing the mosquito challenge on 2 healthy volunteers |
| Impact | No outputs yet - mosquito challenge planned for April 2018 |
| Start Year | 2017 |
| Description | Mahidol University, Bangkok, Thailand |
| Organisation | Mahidol University |
| Country | Thailand |
| Sector | Academic/University |
| PI Contribution | Intellectual input |
| Collaborator Contribution | Provision of Anopheles mosquitoes for CHMI. Testing of mosquito infectivity and infection clonality. Provision of microscopists to diagnose infection during CHMI study in Oxford (April 2018) |
| Impact | No outputs yet - due April 2018 |
| Start Year | 2017 |
| Description | Michael Jarvis |
| Organisation | University of Plymouth |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | cloning of constructs for creation of stable cell lines |
| Collaborator Contribution | supplied recombinant CMV vaccine vector expressing Ebola glycoprotein for immunogenicity testing in mice |
| Impact | no outcomes yet, immunogenicity experiments ongoing, cell line creation ongoing |
| Start Year | 2017 |
| Description | Pharmgenomics - CYP2D6 testing |
| Organisation | PharmGenomics GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | Shipping of clinical blood samples for CYP2D6 genotype testing and compensating PharmGenomics for testing |
| Collaborator Contribution | Testing of clinical blood samples for CYP2D6 genotype testing - in order to predict a healthy trial volunteer's ability to successfully metabolise Primaquine. |
| Impact | To-date 4 volunteers have had blood samples successfully analysed by PharmGenomics. This has contributed to assessment of their eligibility for the VAC068 CHMI P. Vivax study. |
| Start Year | 2017 |
| Description | Rajat Rohatgi |
| Organisation | Stanford University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | My laboratory has been engaged in a close and productive collaboration with Rajat Rohatgi's lab at Stanford University over the past two years to understand the structural and mechanistic basis of Smo activation by Shh and by various Smo ligands. Our collaboration on Smoothened has already produced a paper in eLife (2013), which reported the long-sought-after high-resolution crystal structure of the Smo cysteine-rich domain (CRD). I note that the lack of this structure has been a major roadblock in the field; for comparison, the structures of Frizzled CRDs (the closest relatives of the Smo CRD) were reported in 2001. Guided by this structure, the Rohatgi lab used their expertise in Hedgehog signalling assays, oxysterol chemical biology, and microscopy to define, in molecular detail, a hydrophobic groove on the surface of the CRD that binds to oxysterols. This work was made possible by the ideal complement between our expertise in protein engineering/production and crystallography and the Rohatgi lab's development of oxysterol binding assays and a comprehensive panel of Hh signalling assays. We are actively working on crystallizing ligand-bound versions of the CRD and of larger Smo constructs that include both the CRD and the transmembrane (TM) domain. The Rohatgi lab's discovery of a set of CRD ligands that can function as agonists, antagonists and partial agonists are of particular interest since they provide the opportunity to solve structures of Smo in multiple conformational states. In addition, their comprehensive mutagenesis studies to understand the interactions between the CRD and the TM domains will be particularly relevant to our structural approach this same problem. |
| Collaborator Contribution | see above |
| Impact | - 9 publications: Kinnebrew et al Elife. 2019 Oct 30;8. pii: e50051 (PMID: 31657721) Rudolf et al Nat Chem Biol. 2019 Oct;15(10):975-982 (PMID: 31548691). Kowatsch et al Curr Opin Struct Biol. 2019 Aug;57:204-214 ( PMID: 31247512). Kong et al Development. 2019 May 15;146(10) (PMID: 31092502). Hedger et al Structure. 2019 Mar 5;27(3):549-559 (PMID: 30595453) Byrne et al Curr Opin Cell Biol. 2018 Apr;51:81-88 (PMID: 29268141). Luchetti et al Elife. 2016 Oct 5;5. pii: e20304 (PMID: 27705744). Byrne et al Nature. 2016 Jul 28;535(7613):517-522 (PMID: 27437577). Nachtergaele et al Elife. 2013 Oct 29;2:e01340 (PMID: 24171105). |
| Start Year | 2011 |
| Description | Rob Moon LSHTM |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Assay setup for transgenic P. knowlesi parasites to assist vaccine testing to P. vivax. |
| Collaborator Contribution | Development of transgenic P. knowlesi parasites to assist vaccine testing to P. vivax. |
| Impact | Joint publication and MRC CiC funding |
| Start Year | 2017 |
| Description | Rober Moon |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Experience with growth inhibition assay for Plasmodium falciparum |
| Collaborator Contribution | Provided transgenic Plasmodium knowlesi for the a growth inhibition assay against Plasmodium vivax |
| Impact | Establishment of the transgenic P. knowlesi growth inhibition assay for the in vitro assessment of the efficacy of vaccines/intervention strategies against P. vivax malaria at the Jenner Institute |
| Start Year | 2018 |
| Description | Sanger Institute |
| Organisation | The Wellcome Trust Sanger Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Intellectual input and access to data. |
| Collaborator Contribution | Transcriptomics work - both host response and parasite by RNAseq. Genome sequencing of parasite and DNA extraction to test clonality of infection |
| Impact | No outputs yet as samples not to be obtained and analysed until April 2018 |
| Start Year | 2017 |
| Description | University of Edinburgh, UK |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Intellectual input and access to data |
| Collaborator Contribution | Transcriptomics work - both host response and parasite by RNAseq |
| Impact | No outputs yet |
| Start Year | 2017 |
| Description | WRAIR, USA |
| Organisation | Walter Reed Army Institute of Research |
| Country | United States |
| Sector | Public |
| PI Contribution | Shipping of human plasma samples to WRAIR under appropriate preservation conditions. Compensating WRAIR for the sample analysis. |
| Collaborator Contribution | WRAIR agrees to: •Analyze submitted human plasma samples for levels of primaquine and its metabolite carboxyprimaquine. •Report analyte levels to the study Principal Investigators. •Store samples until study closeout. •Dispose of samples according to relevant protocols. |
| Impact | No outputs yet - clincal samples are to be sent to WRAIR for analysis later this month |
| Start Year | 2018 |
| Description | XChem screening at Diamond Light Source |
| Organisation | Diamond Light Source |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Performed fragment screening at Diamond's XChem facility |
| Collaborator Contribution | Provided access to the XChem facility, including over 30 hours of beamtime at beamline I04-1. |
| Impact | Fragment hits against four different target proteins. |
| Start Year | 2017 |
| Title | Gremlin1 antagonist for the prevention and treatment of cancer |
| Description | Use of anti-grem1 antibody in cancer treatment |
| IP Reference | 19734460.9-1112 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | Yes |
| Impact | Phase1 clinical trial in UK |
| Title | Anti-Grem1 antibody |
| Description | Anti-grem1 antibody developed by UCB pharma and tested preclinically in Oxford with funding from UCB, CRUK, Wellcome, and MRC confidence in concept |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Patent Publications pending |
| Title | P. vivax vaccine |
| Description | Viral vectored vaccine against blood-stage Plasmodium vivax - supported by MRC DPFS grant. Phase Ia clinical trial commenced in April 2013 and now completed. Phase IIa funding secured from EC Horizon 2020 - efficacy trial now completed and published. |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2022 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| UKCRN/ISCTN Identifier | NCT01816113 and NCT04009096 |
| Impact | Grant income. Publications in preparation. |
| URL | https://clinicaltrials.gov/ct2/show/NCT01816113?term=NCT01816113&rank=1 |
| Company Name | LIME BIOSCIENCES LTD |
| Description | Exploiting a novel large DNA assemble technology for pharmaceutical development. |
| Year Established | 2019 |
| Impact | N/A |
| Company Name | GYREOX LIMITED |
| Description | The Company is focussed on creating novel medicines addressing complex intra-cellular targets in a wide range of diseases. Its proprietary platform technology is based on a combination of chemistry and synthetic biology deploying a set of rationally engineered enzymes. |
| Year Established | 2019 |
| Impact | GyreOx's proprietary discovery platform creates unique Gyrocycle™ highly modified macrocyclic peptides, which combine the target-engagement power of biologics with the cell-entry ability of small molecules. |
| Website | http://www.gyreox.com/ |
| Description | 2018 Rayleigh lecture at Harrow School - Paul Fairchild Project |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Invited lecture at Harrow School which provided an opportunity to engage the next generation of scientists in the fields of stem cell biology and immunotherapy and engage interest in arranging placements in the laboratory. |
| Year(s) Of Engagement Activity | 2018 |
| Description | AIMday Antimicrobial resistance |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A workshop where businesses proposed their research questions to experts, creating a discussion, brainstorming and generation of novel ideas by academics / other attendees |
| Year(s) Of Engagement Activity | 2019 |
| Description | Cafe Scientifique |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Gave a talk on cancer immunotherapy organised by secondary school students aiming for public. 10-20 people, including students and local public attended, and the talk was followed by questions and discussion. |
| Year(s) Of Engagement Activity | 2016,2017 |
| Description | Faraday Institute Summer School - 'Ethical challenges of stem cells and reproductive technologies' - Paul Fairchild Project |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | Lectures as part of the Faraday Institute Summer School, Cambridge on the topic of 'Ethical challenges of stem cells and reproductive technologies' |
| Year(s) Of Engagement Activity | 2019 |
| Description | Industry engagement with GSK |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | GSK collaboration developed acquired ChAd63 vector |
| Year(s) Of Engagement Activity | 2021 |
| Description | Industry engagement with Imaxio |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Clinical development of serum in partnership with Imaxio |
| Year(s) Of Engagement Activity | 2021 |
| Description | Industry engagement with Novavax |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Currently entering serum licensing deal |
| Year(s) Of Engagement Activity | 2021 |
| Description | Industry engagement with the Serum Institute of India |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Vaccine license deal in discussion with the Serum Institute of India |
| Year(s) Of Engagement Activity | 2021 |
| Description | Invited talk for the Translationnal Reserach Office |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | A information meeting / workshop to provide information to research scientists on translational funding schemes (application, difficulties, further funding) |
| Year(s) Of Engagement Activity | 2019 |
| Description | Keynote speaker at the Faraday Institute Summer School, Cambridge |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Invited lecture on the 'Ethical challenges of stem cells and reproductive technologies'. The lecture elicited significant debate among attendees. As a result of this activity, I was invited to deliver a series of three lectrues on similar subjects across India. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Publicity around publication of project results - Shoumo Bhattacharya Project |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Media coverage: Front page write up and editorial in The Weekend i newspaper: 21/22 April 2018 |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://inews.co.uk/news/health/tick-saliva-heart-lung-arthritis-crohns-alzheimers-heart-disease-300... |
| Description | Romney Street Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation and debate with the Romney Street Group, |
| Year(s) Of Engagement Activity | 2020 |
| Description | Royal Society Summer Science Exhibition 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Summer Science Exhibition 2018 at the Royal Society - 1000+ people per day from the general public for 7 days. Exhibit on "designer malaria vaccines" |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://royalsociety.org/science-events-and-lectures/2018/summer-science-exhibition/exhibits/designe... |
| Description | STEM Networking |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | STEM networking event including STEM ambassadors, Teachers from Oxfordshire Schools and representatives from Abbott Diabetes Care Ltd. |
| Year(s) Of Engagement Activity | 2017 |
| Description | School visit (St gabriels) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | A lecture at a secondary school, intended for years 13 and above (A levels). The intended purpose was to engage / teach about vaccines and how they work, how they are developped, and what is the typical job /career of a research scientist |
| Year(s) Of Engagement Activity | 2019 |
| Description | The Cherwell School Annual Careers Convention |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Attended annual school careers convention. Several 100 parents and pupils (years 9-13) attended and I provided advice on careers in biological and medical research. The school reported favourable feedback, I was able to help some students discuss the most relevant A level and GCSE subjects and have been invited back for next year. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Women in Science Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Women in Science Day at St Catherine's College in Oxford. Research talk and panel discussion about careers in Science. Approximately 40 sixth form students attended from around the country. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Women in Science Event at St Catherine's College, University of Oxford |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Gave a talk on my research and career journey to approximately 40 sixth form students from across the UK at St Catherine's College, University of Oxford. A panel discussion enabled further engagement with the girls who were interested in how to have a successful career in science. We received favourable feedback and our aim was to encourage young women to study science and apply to Oxford. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Year 8 Human Library at The Cherwell School Oxford |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Career event discussing my professional role with groups of school children. |
| Year(s) Of Engagement Activity | 2019 |